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Abstract
The epidemiology of invasive fungal infections (IFIs) after liver transplantation (LT) is continuing to evolve in the current era of antifungal
prophylactic therapy. This multicenter retrospective cohort study aimed to evaluate the epidemiology, risk factors, and outcomes of
IFIs among LT recipients in the current era.
We analyzed a total of 482 LT recipients aged 18 years and older who were admitted to 3 tertiary hospitals in Korea between
January 2009 and February 2012.
Twenty-four episodes of IFIs occurred in 23patients (4.77%; 23/482).Of these episodes, 20were proven cases and4were probable
cases according to EORTC/MSG criteria. Among these cases, IFI developed within 30 days of transplantation in 47.8% of recipients,
from 31 to 180 days in 34.8% of recipients, and from 181 to 365 days in 17.4%of recipients. Themost common isolates wereCandida
species (n=12, 52.2%;Candida albicans, 6 cases;Candida tropicalis, 1 case;Candida glabrata, 1 case;Candida parapsilosis, 1 case;
and unspecified Candida species, 1 case) and Aspergillus species (n=7, 30.4%). The mortality in patients with IFIs was significantly
higher than that in patientswithout IFIs (47.83% [11/23] vs 7.18% [33/459],P< .001). The incidence of late-onset IFIs is increasing in the
antifungal prophylactic era, and fluconazole-resistant non-albicans Candida species have not yet emerged in Korea.
Abbreviations: CI = confidential interval, IFI = invasive fungal infections, LT = liver transplant, OR = odds ratio.
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Infection after transplantation is a major factor affecting the
outcome of transplant recipients. Although the incidence of
invasive fungal infections (IFIs) is not higher than the incidence ofEditor: Kelvin Ng.
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1are associated with high mortality of 65% to 90% for invasive
aspergillosis and 30% to 50% for candidiasis.[1,2]
Advances in the diagnosis of IFIs, improvement in immuno-
suppressive agents, and refinement of surgical techniques have
resulted in a decline in the incidence of post-transplant IFIs
since the mid-1990s.[3] The Infectious Disease Society of
America guidelines in 2009 recommended antifungal prophy-
laxis for high-risk liver transplant (LT) recipients, and some
studies have showed that antifungal prophylaxis among LT
recipients has reduced the incidence of IFIs.[4–6] In Korea,
a consensus for antifungal prophylaxis among LT patients
has not been achieved. Antifungal prophylaxis was rarely used
due to insurance problem, drug toxicity, resistance, break-
through infection, and cost-effectiveness. However, recently,
practices of prophylactic therapy have been changing, and the
studies on fungal infections in LT recipients are continuing to
evolve.
Several preoperative, perioperative, and postoperative risk
factors have been associated with IFIs and mortality among LT
recipients.[2,4,5] Identifying risk factors for IFIs can guide the
timely use of prophylactic agents or early treatment of IFI among
high-risk LT recipients, potentially improving the outcomes for
LT patients. In Korea, there are limited center-specific studies in
the epidemiology of IFIs and risk factors among LT recipients.
The aim of this multicenter retrospective cohort study was to
examine the incidence of IFI, risk factors, and clinical outcomes
among LT patients in Korea 1 year after LT in the era of anti-
fungal prophylaxis.
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2.1. Study design and patients
The electronic medical records from 3 tertiary teaching hospitals
in Korea were reviewed for all LT recipients over 18 years of age
between January 2009 and February 2012. We excluded patients
diagnosed with IFI at the time of transplantation. Diagnosis of IFI
included individuals that met any of the proven, probable, or
possible cases of European Organization for Research and
Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
consensus criteria for IFI diagnosis.[6]2.2. Definition
IFI was defined according to EORTC/MSG consensus.[6] Fungal
colonization was defined as the presence of fungus in the absence
of clinical symptoms or evidence of infection within 3 months of
transplantation. Prior use of an antifungal agent was defined
as administration of antifungal agents within 3 months of
transplantation.2.3. Prophylactic strategy
Prophylactic antibiotics for LT were different for individual cases.
Decision for antifungal prophylaxis was physician dependent.2.4. Data collection
We reviewed medical records for demographic characteristics as
well as preoperative, surgical and postoperative factors. We
evaluated the medical records information regarding fungal
infections including etiology and sites of infection within one year
after transplantation through clinical data, microbiologic data,
histopathologic data, radiologic data, and serologic data.
Preoperative factors included clinical data (donor type, age,
body mass index (BMI), model for end-stage liver disease
(MELD) score, child Pugh score, antibiotic prophylaxis, dialysis,
and indication for transplant) and laboratory data within 7 days
prior to the liver transplantation. Fungal colonization was
defined as the growth of fungus in clinical samples before
transplantation without clinical signs or symptoms of infection.
Surgical factors included operation time (min), intraoperative
packed RBC transfusion volume (Unit) and anhepatic time (min).
Postoperative factors included intravenous hyperalimentation,
mechanical ventilation, presence of CMV infection, acute
rejection and presence of IFI.
2.5. Outcomes
The primary endpoint of this study was to identify the incidence
of IFIs after LT.We used 1-year mortality after liver transplant as
a secondary outcome.
2.6. Ethics statement
This study was approved by the institutional review board of
each hospital. All the data collected during this study were kept
confidential.2.7. Statistical analysis
Student’s t test or theMann–WhitneyU test was used for analysis
of continuous variables, and the X2 test or Fisher exact test was2used for categorical variables. We analyzed the risk factors
associated with IFIs and mortality using univariate and
multivariate methods. The final model was determined by a
stepwise variable selection method. Survival curves were
generated using the Kaplan–Meier method with log-rank test.
Statistical analyses were performed using SAS Software version
9.2. A P value <.05 was considered statistically significant.3. Results
3.1. Baseline characteristics
Of 487 patients screened in this study, 5 patients were excluded; 2
patients were younger than 18 years old at the time of
transplantation and 3 patients had preoperative IFIs. The
demographic characteristics are shown in Table 1. The median
age was 53 years (range 23–69 years), and 76.8% of patients (n=
370) were male. Diabetes mellitus was the most common
comorbidity (n=119, 24.8%) followed by hypertension (n=100,
20.8%). Liver cirrhosis (n=409, 84.8%) was the most common
indication for transplantation and 51% of patients had
hepatocellular carcinoma. Retransplantation was performed in
1.9% of patients (n=9). The median MELD score was 14 (range
6–40), and a Child Pugh score C was found in 36.8% (n=175) of
patients.
3.2. Incidence of fungal infection
Among 482 patients, IFIs occurred in 23 patients (4.8%; 23/482)
with 24 episodes, of which 20 were proven cases and 4 were
probable cases according to EORTC/MSG criteria. The most
common etiology for IFI was Candida species in 12 patients
(52.2%; Candida albicans, 6 cases; Candida tropicalis, 1 case;
Candida glabrata, 1 case; Candida parapsilosis, 1 case; and
unspecified Candida species, 1 case). Aspergillus species were
found in 7 patients (30.4%) including 3 cases of Aspergillus
fumigatus. Cryptococcus was isolated in 1 patient. The sites
affected by IFI were the intra-abdominal space (n=9, 39.1%), the
lung (n=8, 34.8%), catheter (n=6, 26.1%), urinary tract (n=2,
8.7%) and skin and soft tissues (n=1, 4.4%).
Median time to first IFI after LT was 38 days (range 2–339
days). Development of IFI occurred within 30 days after
transplantation in 47.8% (n=11) of recipients, from 31 to
180 days in 34.8% (n=8) of patients and from 181 to 365 days in
17.4% (n=5) of patients. The causative organisms of IFIs
according these time periods are summarized in Table 2.
3.3. Risk factors for IFI
In univariate analysis, the risk factors associated IFI were prior use
of antifungal therapy (OR 13.62, 95%CI 3.04–61.03, P= .0006),
pretransplant dialysis (OR 5.28, 95% CI 1.48–12.37, P= .007),
high MELD score (OR 5.93, 95% CI 1.48–23.71, P= .01),
intraoperative RBC≥14 units (OR 2.23, 95% CI 0.95–5.22,
P= .06), anhepatic time≥122minutes (OR 3.80, 95% CI 1.12–
12.89, P= .03), CMV infection (OR 4.12, 95% CI 1.71–9.92,
P= .001), fungal colonization (OR 15.61, 95% CI 5.64–43.22,
P< .0001), bacterial infection (OR 6.04, 95% CI 1.91–19.08,
P= .002) and hyperalimentation (OR 3.80, 95% CI 3.00–17.69,
P< .0001) (Table 3). Multivariate analysis showed that indepen-
dent risk factors for IFI were history of antifungal agents (OR
28.47, 95% CI 3.33–243.7, P= .002), retransplantation
(OR 15.69, 95% CI 2.08–118.52, P= .007), fungal colonization
Table 1
Demographic and clinical characteristics.
Total (n=482) Prophylaxis (N=196) Non-prophylaxis (N=286) P value
Age, years, median (IQR) 53 (10) 52 (9.5) 53 (9.0) .404
Male sex 370 (76.8%) 160 (81.6%) 210 (73.4%) .036
BMI, kg/m2, .228
<18.50 20 (4.2%) 11 (5.6%) 9 (3.2%)
18.50–24.99 266 (55.9%) 102 (52.0%) 164 (58.6%)
25.00–29.99 190 (39.9%) 83 (42.4%) 107 (28.2%)
≥30.00 0 0 0
Comorbidity
Diabetes mellitus 119 (24.7%) 50 (25.5%) 69 (24.1%) .607
Hypertension 100 (20.8%) 35 (17.9%) 65 (22.7%) .729
Deceased donor 65 (13.5%) 24 (12.2%) 41 (14.3%) .509
ABO incompatible donor 25 (5.29%) 21 (11.2%) 4 (1.4%) <.001
Retransplantation 9 (1.9%) 3 (1.5%) 6 (2.1%) .744
Indication for transplantation .21
Liver cirrhosis 409 (84.8%) 182 (92.9%) 227 (79.4%)
Hepatocellular carcinoma 246 (51.0%) 102 (52.0%) 144 (50.4%)
Fulminant hepatic failure 44 (9.1%) 13 (6.6%) 31 (0.8%)
Others 3 (0.6%) 2 (1.0%) 1 (0.35%)
Child Pugh score C 175 (36.8%) 64 (32.7%) 111 (39.8%) .273
MELD score, median (IQR) 14 (13) 15 (12) 14 (15) .905
Fungal colonization before transplantation 104 (21.6%) 38 (19.4%) 66 (23.1%) .333
Pretransplant dialysis 33 (6.8%) 10 (5.1%) 23 (8.04%) .209
Pretransplant ICU stay 19 (3.9%) 6 (3.1%) 13 (4.5%) .410
Acute rejection 20 (4.2%) 6 (3.1%) 14 (4.9%) .321
Length of post-transplant ICU stay, days, median (IQR) 5 (4) 4 (5.5) 6 (3) <.0001
Bacterial infection 246 (51.0%) 64 (32.7%) 182 (63.6%) <.0001
ICU= intensive care unit, IQR= interquartile range, MELD=model for end-stage liver disease.
Kim et al. Medicine (2019) 98:26 www.md-journal.com(OR 14.89, 95%CI 4.07–54.42,P= .007), and hyperalimentation
(OR 6.2, 95% CI 2.1–17.70, P= .0009) (Table 3).
3.4. Secondary outcomes
The 1-year overall mortality after transplantation was 9.13%
(n=44), and infection-related mortality was 4.9% (n=24). Four
patients experienced fungus-related deaths. The mortality in
patients with IFIs was significantly higher than in those without
IFIs (47.83% [11/23] vs 7.18% [33/459], P< .0001). The
Kaplan-Meier survival curves for patients with IFI and those
without IFI are shown in Figure 1.Table 2
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33.5. Antifungal prophylaxis and outcomes
Systemic antifungal prophylaxis was administrated in 40.6%
(n=196) of a total of 482 patients. IFI was found in 9 patients
in antifungal prophylaxis groups and 14 patients in non-
antifungal prophylaxis group (P= .87). There were more ABO-
incompatible donors in prophylaxis group (11.2% [21/196] vs
1.4% [4/286], P< .001). Recipient age (52 years (IQR 9.5) vs
53 years (IQR 9.0), P= .404), MELD score (15 (IQR 12) vs 14
(IQR 15), P= .91), Child Pugh score C (32.7% [64/196] vs
39.8% [111/286], P= .273) and fungal colonization (19.4%















Risk factors for invasive fungal infections.
Variables Univariate analysis Multivariate analysis
P value OR 95% CI P value OR 95% CI
Deceased donor .24 1.85 0.66–5.16
Diabetes mellitus .73 0.84 0.31–2.32
Prior use of antifungal therapy .0006 13.62 3.04–61.03 .002 28.47 3.33– 243.7
Pretransplant dialysis .007 4.28 1.48–12.37
Retransplantation <.0001 19.11 4.75–76.94 .007 15.69 2.08–118.52
MELD score
11–20 (ref10) .11 2.87 0.78–10.63 .48 1.71 0.40–7.42
21–30 .34 2.21 0.43–11.21 .70 0.71 0.12–4.15
31–40 .01 5.93 1.48–23.71 .61 0.63 0.11–3.74
Intraoperative pRBC transfusion ≥ 14 (ref=< 14) .06 2.23 0.95–5.22
Anhepatic time, min ≥122 (ref=< 122) .03 3.80 1.12–12.89
CMV infection .001 4.12 1.71–9.92
Fungal colonization <.0001 15.61 5.64–43.22 <.0001 14.89 4.07–54.42
Fungal prophylaxis .87 0.94 0.40–2.20
Bacterial infection .002 6.04 1.91–19.08 .13 2.94 0.72–12.05
Hyperalimentation <.0001 7.28 3.00–17.69 .0009 6.1 2.1–17.70
Acute rejection .27 2.33 0.51–10.72
CMV= cytomegalovirus, MELD=model for end-stage liver disease, pRBC=packed RBC.
Kim et al. Medicine (2019) 98:26 Medicinebetween the 2 groups (Table 1). Patients in prophylaxis group
had shorter duration ICU stays post-transplantation (4 days
(IQR 5.5) vs 6 days (IQR 3), P< .0001) and developed bacterial
infection less frequently (32.7% [64/194] vs 63.6% [182/286],
P< .0001) than those in non-prophylaxis group. However 1-
year overall mortality was not different between the 2 groups
(10.8% [21/194] vs 8.0% [23/286], P= .30) (Fig. 2). The
median time to the first occurrence of IFI after LT was 79 days
(IQR 66) in the prophylaxis group and 22.5 days (IQR 48) in
the non-prophylaxis group (P= .643). The rate of first IFI
occurrence within 90 days of transplantation was notFigure 1. Kaplan-Meier survival curve
4statistically different between the 2 groups (66.7% [6/9] vs
78.6% [11/14], P= .643)
3.6. Risk factors for mortality
Univariate analysis revealed that the risk factors associated with
mortality were deceased donor organ transplant (OR 5.23, 95%
CI 2.87–9.55, P< .0001), preoperative dialysis (OR 6.60, 95%
CI 3.39–12.82, P< .0001), MELD score, presence of IFI (OR
7.74, 95% CI 3.90–15.34, P< .0001), bacterial infection
(OR 6.29, 95% CI 2.66–14.88, P< .0001), hyperalimentations for patients with and without IFI.
Figure 2. Kaplan-Meier survival curves stratified by use of antifungal prophylaxis.
Kim et al. Medicine (2019) 98:26 www.md-journal.com(OR 2.41, 95% CI 1.32–4.40, P= .004), retransplantation (OR
4.50, 95% CI 1.39–14.55, P= .01), fungal colonization (OR
2.87, 95% CI 1.58–5.21, P= .0005), acute rejection (OR 3.14,
95% CI 1.24–7.96, P= .02), CMV infection (OR 2.20, 95% CI
1.13–4.27, P=0.02) and use of mechanical ventilation (OR 3.67,
95% CI 1.14–1.86, P= .02) (Table 4). Multivariate analysis
revealed that deceased donor (OR 13.00, 95% CI 5.1–33.1,
P< .0001), presence of IFI (OR 6.72, 95% CI 2.62–17.22,
P< .0001), bacterial infection (OR 2.83, 95% CI 1.10–7.26,
P= .0001) and hyperalimentation (OR 3.45, 95% CI 1.51–7.85,
P= .003) were independent risk factors for mortality after
transplantation (Table 4).Table 4
Risk factors for mortality.
Variables Univariate analysis
P value HR
Deceased donor <.0001 5.23 2.8
Diabetes mellitus .28 0.66 0.
Preoperative dialysis <.0001 6.60 3.3
MELD score
11–20 (ref10) .44 1.44 0.
21–30 .06 2.57 0.
31–40 <.0001 6.67 2.7
Presence of IFI <.0001 7.74 3.9
Bacterial infection <.0001 6.29 2.6
Hyperalimentation .004 2.41 1.
Retransplantation .01 4.50 1.3
Fugal colonization .0005 2.87 1.
Acute rejection .02 3.14 1.
CMV infection .02 2.20 1.
Mechanical ventilation .02 3.67 1.
CMV= cytomegalovirus, IFI= invasive fungal infection, MELD=model for end-stage liver disease.
54. Discussion
Fungal infection is associated with high morbidity and mortality
among patients with LT.[7,8] The present retrospective study from
3 tertiary hospitals in Korea found that IFIs developed in 4.8% of
LT recipients. The mortality rate in patients with IFIs after LT
approached 50%. Recently, the incidence of IFIs has decreased
because of improvement in surgical techniques, advances in
immunosuppressive agents, and better antifungal prophylax-
is.[7,9,10] The incidence of IFI is reported to be 7% to 42% in solid
organ transplant recipients and in our previous single center
study, we reported that the rate of fungal infection after LT was
5.4%.[1,11–13] Our study revealed a trend towards a slightly lowerMultivariate analysis
95% CI P value HR 95% CI
70–9.55 <.0001 13.00 5.1–33.1
36–1.42
9–12.82
57–3.65 .56 0.74 0.38–5.96
93–7.08 .15 0.94 0.1–1.42
6–16.09 .73 1.22 0.18–3.35
0–15.34 <.0001 6.72 2.62–17.22
6–14.88 .03 2.83 1.10–7.26






Kim et al. Medicine (2019) 98:26 Medicineincidence of IFI compared to our previous findings. No
standardized protocol for antifungal prophylaxis in LT recipients
was in place as shown in our previous study, and antifungal
prophylaxis in transplant recipients was not common practice in
most centers in Korea.[11] However, recently, there has been an
increasing trend toward treatment using antifungal prophylaxis
in solid organ transplant recipients in Korea. In this study, about
40% of the patients underwent systemic antifungal prophylaxis
despite the limitation of insurance policies regarding the use of
antifungal prophylaxis in Korea. Our study showed that the
patients who received antifungal prophylaxis had a higher
percentage of ABO incompatible donors and post-transplant
bacterial infection. These findings suggest that antifungal
prophylactic strategies have shifted to target high-risk LT
patients in Korea. In addition, we observed that about 18% of
IFIs developed in recipients after 6 months of transplantation,
while the rest developed within 6 months of transplantation. In
our previous study, only one case of an IFI had developed after 6
months of transplantation in LT patients without antifungal
prophylaxis.[11] In general, 6 months after transplantation, most
patients suffer from community-onset infectious disease because
of maintenance minimal immunosuppressive therapy with good
graft function.[14] However, some studies have reported a trend
toward later onset invasive aspergillosis in transplant
patients.[15,16] The time to first occurrence of IFI was longer in
antifungal prophylaxis group, although significant difference was
found. The changes of antifungal strategies in Korea seem to
cause the delayed occurrence of fungal infection.
In this study, patients in non-prophylaxis group did not show
unfavorable outcomes. This may be due to bias for patient
selection, and further randomized controlled studies to analyze
the effect of antifungal prophylaxis on clinical outcomes will be
needed. However our result supports the use of targeted
antifungal prophylaxis in high-risk patients
Raghuram et al reported that non-albicans Candida species
accounted for 55% of IFIs, and only 43% of Candida isolates
were fluconazole-susceptible in LT recipients.[5]Candida species
were the predominant pathogen causing fungal infection in our
study, withC. albicans constituting half of allCandida infections,
and C. glabrata was found in only 1 case. Until now, our finding
suggests that fluconazole-resistant Candida species have not
emerged yet among LT patients in Korea, although we did not
analyze the resistance pattern of Candida species. One study of
invasive candidiasis in an Asia-Pacific area showed that non-
albicans Candida species account for more infections than C.
albicans, and fluconazole resistance was found in 18.2% of C.
tropicalis, 5.2% of C. glabrata and in 2.2% of C. tropicalis
isolates.[17] There is an increasing trend of fluconazole resistance
especially in non-albicans Candida species, and analyzing the
resistance pattern in Candida species will guide antifungal drug
choice for IFIs among LT patients in Korea.
Several studies reported that the risk factors for IFIs in LT
patients were CMV disease, retransplantation, dialysis, fulmi-
nant hepatic failure, fungal colonization and prolonged opera-
tion time.[2,7,18] A meta-analysis showed antifungal prophylaxis,
especially fluconazole or liposomal amphotericin B, reduced the
rate of IFI and IFI-related mortality.[19] In our study, we also
found that fungal colonization, retransplantation, and hyperali-
mentation were associated with IFIs among LT patients. Central
venous catheterization was needed for hyperalimentation among
LT patients, and catheter use may be a source of Candida
infection. In addition, catheter-related fungal infection in LT6patients occurred in 26% of cases, indicating the need for further
efforts to decrease catheter-related infection.
Our study has some limitations. First, this is a retrospective
study. There was lack of regional data for fungal complications
among LT recipients in Korea. This study included large number
of cases (482 LT patients) from 3major transplantation centers in
Korea, and our data could overcome the limitations associated
with a single-center study. Second, the use of antifungal
prophylaxis and treatment was physician dependent, and this
could have influenced the risk factors or outcomes. However,
there are some issues for antifungal prophylaxis in Korea because
of insurance policies and cost, and it is notable that this study was
reflects current trends in clinical practice. Third, this study did not
evaluate the effect of antifungal treatment on outcome.5. Conclusions
The incidence of late-onset IFIs is increasing in the antifungal
prophylactic era, and fluconazole-resistant non-albicans Candida
species have not yet emerged in Korea. IFIs remain a significant
predictor of mortality in the prophylactic era although there has
been decreasing trend towards incidence of IFI in Korea. Early
identification of patients with high-risk for IFIs is crucial to
decrease the mortality (especially in retransplantation), fungal
colonization, and hyperalimentation cases.Author contributions
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